Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Bone Biologics (NASDAQ:BBLG)

CollPlant Biotechnologies (NASDAQ:CLGN) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

CollPlant Biotechnologies has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Institutional & Insider Ownership

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 13.0% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CollPlant Biotechnologies and Bone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-64.05%	-22.17%	-18.84%
Bone Biologics	N/A	-151.99%	-121.03%

Analyst Ratings

This is a breakdown of recent ratings for CollPlant Biotechnologies and Bone Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	0	0	1	0	3.00
Bone Biologics	0	0	0	0	N/A

CollPlant Biotechnologies presently has a consensus target price of $11.00, indicating a potential upside of 83.33%. Given CollPlant Biotechnologies’ higher probable upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than Bone Biologics.

Valuation and Earnings

This table compares CollPlant Biotechnologies and Bone Biologics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$10.96 million	6.27	-$7.02 million	($0.64)	-9.38
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A

CollPlant Biotechnologies has higher revenue and earnings than Bone Biologics.

Summary

CollPlant Biotechnologies beats Bone Biologics on 6 of the 10 factors compared between the two stocks.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.